Cargando…

Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma

BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are considered to be more effective than chemotherapy in the treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). However, in addition to EGFR-sensitive mutations, the genetic factors that affect the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Hualin, Liu, Meilian, Dai, Zhiwei, Li, Shujun, Luo, Yiping, Wang, Yongcun, Su, Wenmei, Cai, Weijing, Yang, Donghong, Huang, Jian, Yang, Zhixiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481595/ https://www.ncbi.nlm.nih.gov/pubmed/32953500 http://dx.doi.org/10.21037/tlcr-20-679

Ejemplares similares

Comprehensive Analysis of DMRT3 as a Potential Biomarker Associated with the Immune Infiltration in a Pan-Cancer Analysis and Validation in Lung Adenocarcinoma
por: Yang, Donghong, et al.
Publicado: (2022)

Clinical and pathological characteristics of 11 NSCLC patients with c-MET exon 14 skipping
por: Chen, Hualin, et al.
Publicado: (2022)

Activation of the Hedgehog pathway mediates resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer
por: Chen, Hualin, et al.
Publicado: (2022)

Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis: A single institution retrospective analysis
por: Chen, Hualin, et al.
Publicado: (2018)

Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations
por: ZHANG, Guowei, et al.
Publicado: (2022)

A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
por: Lee, Ki-Chang, et al.
Publicado: (2021)

The Value of Serum Exosomal miR-184 in the Diagnosis of NSCLC
por: Li, Shujun, et al.
Publicado: (2022)

Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report
por: Fan, Jun, et al.
Publicado: (2020)

Concomitant genetic alterations having greater impact on the clinical benefit of EGFR‐TKIs in EGFR‐mutant advanced NSCLC than BIM deletion polymorphism
por: Liu, Si‐Yang, et al.
Publicado: (2020)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma
por: Pan, Deng, et al.
Publicado: (2019)

Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors
por: Chang, Shih-Chieh, et al.
Publicado: (2019)

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
por: Xie, Yalin, et al.
Publicado: (2021)

Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature
por: Li, Yuping, et al.
Publicado: (2017)

Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma?
por: Khalifa, Mahmoud A, et al.
Publicado: (2006)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
por: Ortiz-Zapater, Elena, et al.
Publicado: (2017)

Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML
por: Watanabe, Kousuke, et al.
Publicado: (2020)

Genetic Associations of Visfatin Polymorphisms with EGFR Status and Clinicopathologic Characteristics in Lung Adenocarcinoma
por: Chang, Sunny Li-Yun, et al.
Publicado: (2022)

Association of EGFR 1 Gene Alteration and their Association with Lung Adenocarcinoma Patients
por: Beg, Mirza Masroor Ali, et al.
Publicado: (2019)

The Relationship between TTF-1 Expression and EGFR Mutations in Lung Adenocarcinomas
por: Shanzhi, Wan, et al.
Publicado: (2014)

Imaging of synchronous multiple primary lung adenocarcinoma with concomitant EGFR and KRAS mutations: a case report and review of the literature
por: Ma, Jing-Wen, et al.
Publicado: (2021)

A novel ARMS-based assay for the quantification of EGFR mutations in patients with lung adenocarcinoma
por: Zhu, Yazhen, et al.
Publicado: (2018)

Stevens–Johnson syndrome induced by toripalimab in a previously EGFR-TKI-treated advanced lung adenocarcinoma patient harboring EGFR mutations 19 del/T790M/C797S in trans and cis: a case report
por: Chen, Yang, et al.
Publicado: (2023)

Association of EGFR mutations and HMGB1 genetic polymorphisms in lung adenocarcinoma patients
por: Wu, Yi-Liang, et al.
Publicado: (2019)

Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status
por: Hsu, Jim, et al.
Publicado: (2022)

Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status
por: Planck, Maria, et al.
Publicado: (2013)

Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC Patients
por: Liang, Hengrui, et al.
Publicado: (2020)

LINC00857 knockdown inhibits cell proliferation and induces apoptosis via involving STAT3 and MET oncogenic proteins in esophageal adenocarcinoma
por: Su, Wenmei, et al.
Publicado: (2019)

Malignant pleural mesothelioma showing rare morphology indistinguishable from myxofibrosarcoma concomitant with EGFR-mutated lung adenocarcinoma: A case report
por: Onagi, Hiroko, et al.
Publicado: (2021)

Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
por: Su, Kang-Yi, et al.
Publicado: (2018)

NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment
por: Koba, Hayato, et al.
Publicado: (2021)

Associations of TIMP-3 Genetic Polymorphisms with EGFR Statuses and Cancer Clinicopathologic Development in Lung Adenocarcinoma Patients
por: Chang, Jer-Hwa, et al.
Publicado: (2020)

The Clinical Characteristics and Prognosis of Different Age Patients with Lung Cancer
por: Chen, Xiaorao, et al.
Publicado: (2020)

Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis
por: Ye, Chenyang, et al.
Publicado: (2016)

Endometrial Adenocarcinoma with Concomitant Left Atrial Myxoma
por: Abaid, Lisa N., et al.
Publicado: (2009)

LncRNA MIR22HG abrogation inhibits proliferation and induces apoptosis in esophageal adenocarcinoma cells via activation of the STAT3/c-Myc/FAK signaling
por: Su, Wenmei, et al.
Publicado: (2019)

Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression
por: Cai, Yiran, et al.
Publicado: (2020)

Circular RNA‐mediated ceRNA network was identified in human lung adenocarcinoma by high‐throughput sequencing
por: Chen, Yongyang, et al.
Publicado: (2023)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_18l3a3n6lnh90htg0v7vb9vpqk